-
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
Thursday, November 14, 2024 - 2:00pm | 482The U.S. Food and Drug Administration (FDA) has offered positive feedback to CaaMTech, Inc. on its CT-4201 psilocin prodrug program, specifically endorsing the company's approach to addressing "functional unblinding" in its drug trials. This regulatory milestone not only clears the clinical...
-
Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments
Tuesday, November 12, 2024 - 3:32pm | 818Recent innovations in psychedelics research are laying the groundwork for a potential breakthrough in mental health treatments. The focus is on three new compounds patented by CaaMTech, Inc., designed to address the limitations of traditional psychedelics such as psilocybin and psilocin. According...
-
Exclusive: CaaMTech And Alexander Shulgin Research Institute To Follow Study On Shulgin's Compounds
Wednesday, July 6, 2022 - 11:42am | 445Psychedelic drug discovery & optimization company CaaMTech Inc. and the psychedelics discovery, development & educational organization Alexander Shulgin Research Institute Inc. (ASRI) have recently signed an agreement to carry out structural and chemical analyses to further develop novel...